Akèy › Kansè nan tete › South Dakota
Etid klinik pou Kansè nan tete nan South Dakota
20 etid pou Kansè nan tete ap chèche patisipan nan sit nan South Dakota.
Vil nan South Dakota
Tèks ofisyèl etid la (Anglè)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Avera Cancer Institute, Sioux Falls
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT06982521Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Sanford USD Medical Center, Sioux Falls
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Avera Cancer Institute, Sioux Falls
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06324357A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Avera McKennan Hospital ( Site 0002), Sioux Falls
- Avera Cancer Institute - Yankton ( Site 0089), Yankton
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Sanford Health, Sioux Falls
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sanford Cancer Center, Sioux Falls
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Avera St. Mary's Hospital, Pierre
- Avera Cancer Institute, Sioux Falls
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Sioux Falls
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou Sep 8, 2026 · NCT07647328A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, SD, Pierre
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07405801Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Sanford - Sioux Falls, Sioux Falls
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Avera Cancer Institute-Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute at Pierre, Pierre
- ak 4 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Research Site, Aberdeen
- Research Site, Pierre
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou Aug 19, 2026 · NCT05774951E-Mindfulness Approaches for Living After Breast Cancer
- Rapid City Regional Hospital, Rapid City
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Avera Cancer Institute, Sioux Falls
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Sanford Health, Sioux Falls
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT06757634I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Sanford Clinical Research, Sioux Falls
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, Pierre
- ak 2 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT05142033Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Monument Health Rapid City Hospital, Rapid City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Avera Cancer Institute, Sioux Falls
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT06401421Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.